Kornimate/medical-research-clean huggingface dataset:
young esus patient registry

Conditions: Embolic Stroke of Undetermined Source

Summary: this study seeks to determine the clinical characteristics of young esus patients using diagnostic criteria of the cryptogenic stroke / esus international working group, and to determine the rates of stroke recurrence, death, and hospital readmission in a contemporary cohort of young esus patients during follow-up of up to 18 months.


Eligibility criteria:
inclusion criteria: 1. embolic stroke of undetermined source (esus) within 60 days, defined as: 1. recent esus (including transient ischemic attack with positive neuroimaging) visualized by brain computed tomography (ct) or magnetic resonance imaging (mri) that is not lacunar (i.e., lacunar infarcts are subcortical infarcts ≤ 1.5 cm in the territory of middle cerebral artery or pons; infarcts involving the cerebellum or lateral medulla are not considered as lacunar infarcts). patients with multiple simultaneous acute lacunar infarcts on diffusion weighted imaging may be included. in case of embolic large artery occlusions clearly documented on angiography who undergo successful recanalization, visualization of infarct on neuroimaging is not mandated, and 2. absence of cervical carotid atherosclerotic stenosis (or vertebral and basilar atherosclerotic stenosis in case of posterior circulation stroke), that is \>50%, or occlusion in arteries supplying the area of ischemia, (unless deemed embolic) in ct or magnetic resonance (mr) angiography or conventional angiography or ultrasound, and 3. no history of atrial fibrillation (af), no documented af on 12-lead electrocardiogram or episode of af lasting 6 minutes or longer detected after ≥ 24-hour cardiac rhythm monitoring (holter or telemetry; at least 20 hours acceptable), and 4. no intra-cardiac thrombus on either transesophageal or transthoracic echocardiography, and 5. no other specific cause of stroke identified by routine clinical care (e.g., arteritis, dissection, migraine/vasospasm, drug abuse) 2. age ≥ 21 to ≤ 50 years 3. written informed consent with local regulations governing research in human subjects exclusion criteria: 1. close affiliation with the investigational site; e.g. a close relative of the investigator, dependent person (e.g., employee or student of the investigational site) 2. enrollment in an investigational study on esus 3. if imaging of intracranial arteries are performed by ct or mr angiography, digital subtraction angiography or transcranial doppler: \>50% luminal stenosis or occlusion in arteries supplying the area of ischemia (unless deemed embolic)

Keywords: stroke ischemic stroke cryptogenic stroke embolic stroke of undetermined source esus cerebrovascular disease
objective, passive assessment of lrrk2 carriers

Conditions: Parkinson Disease

Summary: the goal of this project is to identify objective, sensitive, and convenient measures for assessing early signs of parkinson's disease in an at-risk population at home. we will do so by using a wireless sensor and analyzing the radio signals that bounce off patients' bodies, while patients go about their normal life without needing to wear sensors, answer questionnaires, or actively perform any tests.


Eligibility criteria:
inclusion criteria: * at least 50 years of age * able and willing to provide informed consent * english fluency * u.s. resident * lrrk2 g2019s gene carrier, determined by participation in valor-pd * mild parkinsonian signs, determined by modified movement disorder society-unifeid parkinson's disease rating scale (mds-updrs) score from the most recent valor-pd visit * have wifi in their residence * access to a smartphone or tablet exclusion criteria: * inability to complete study activities, as determined by the study team * any medical or psychiatric condition that, in the study team's judgement, would preclude participation * self-reported or valor-pd investigator determined parkinson's disease * any movement disorder (e.g. essential tremor) * currently taking neuroleptics or other drugs known to cause parkinsonism * pregnancy * non-ambulatory status * more than one ambulatory pet in the household\* * more than two individuals in the household (not including participant)\* * these criteria can be waived at the discretion of the investigators
breathing therapy for patients in general practice

Conditions: Mind-Body Therapies

Summary: medically unexplained physical symptoms (mups) capture conditions characterized by symptoms without corresponding objective findings, such as asthenia, low back pain, fibromyalgia, irritable bowel syndrome, or chronic fatigue syndrome. in order to establish the grounds for a rct. this pilot study aims to investigate the effectiveness and feasibility of a 5-week breathing retraining programme on patients who meet the criteria for mups.

medically unexplained physical symptoms (mups) are symptoms without an identifiable organic cause that lead to functional impairment. mups is highly prevalent in general practice consultations. this pilot study aimed to investigate the effectiveness and feasibility of a 5-week breathing retraining program for patients meeting the criteria for mups. the study used a quantitative observational design with pre- and post-intervention measurements. fifteen participants with mups and dysfunctional breathing (assessed by the nijmegen questionnaire) were recruited from two general practitioner offices. the intervention consisted of 5 weekly sessions including education on breathing physiology and weekly breathing exercises focused on nasal breathing and resonance breathing techniques. one week post intervention, improvements were observed in dysfunctional breathing scores, lower symptom severity, higher general well-being, and reduced musculoskeletal pain complaints. at 3 months post-intervention, sustained improvements were seen in dysfunctional breathing, general well-being, musculoskeletal pain, and additionally lower pseudoneurological, gastrointestinal, and allergy complaints, as well as lower overall symptom burden and improved end-tidal co2 levels. the study concluded that the 5-week breathing program showed promising results for improving multiple patient-reported outcomes in mups. recruitment, adherence, and acceptability of the program were satisfactory. a randomized controlled trial is recommended to further evaluate the efficacy of this breathing intervention for mups patients.

Eligibility criteria:
inclusion criteria: * 18 years * dysfunctional breathing, * sufficient laguage skills to fill out forms exclusion criteria: * participants with asthma * participants with,chronic obstructive pulmonary disease * participants with respiratory allergy that is not optimally treated medically.
a study of imc-1 in patients with fibromyalgia

Conditions: Fibromyalgia; Chronic Pain; Myofascial Pain

Summary: this is a randomized, double-blind, placebo-controlled, 16-week study designed to evaluate the hypothesis that tissue-resident herpes virus may be causally related to fibromyalgia symptoms or recurrence. imc-1 is a combination treatment that is designed to suppress this suspected virus and thus alleviate fibromyalgia symptoms.


Eligibility criteria:
inclusion criteria: * diagnosis of fibromyalgia * english speaker exclusion criteria: * rheumatologic diseases * bipolar disease, ocd, severe anxiety, schizophrenia * systemic infection, severe cardiac disease, chronic steroid usage * chronic opioid usage

Keywords: fibromyalgia myofascial
optimizing treatment effects on osa-related clinical and patient-centered outcomes among blacks

Conditions: Obstructive Sleep Apnea

Summary: the study is to maximize efficacy of message delivery to achieve desired obstructive sleep apnea (osa) adherence goal. newly diagnosed black patients (n=390, all genders) from participating sleep clinics will be randomly exposed to either the individually tailored or standard osa messages. investigators will look at an effective and scalable intervention to improve osa-related outcomes: a) clinical cvd and brain health measures and b) patient-centered outcomes. patient-centered and adherence data will be captured via redcap, enabling real-time application of data-driven decision rules while implementing the intervention.


Eligibility criteria:
inclusion criteria: * self-reported race/ethnicity as african american, african, caribbean or black * accessible by phone * no plans to move away within the year * osa diagnosis, consent, including permission to release medical data * physician-diagnosed medical conditions. exclusion criteria: * progressive illnesses in which disability or death is expected within 1 year * impaired cognitive/ functional ability precluding participation * intention to move within the same year of enrollment * family member currently enrolled
oral olanzapine versus haloperidol or diazepam

Conditions: Acute Agitation; Behavioural Emergency

Summary: the purpose of this study is to determine whether oral olanzapine is safer (fewer adverse events) and more effective (shorter time to sedation) than conventional haloperidol or diazepam when used in the management of acute agitation in the emergency.

1. investigate oral use of sedating drugs within a predominantly chinese population, to address this void in international literature impacting the management of acute agitation. 2. the multi-centre randomised clinical trial will determine the safety and efficacy of oral olanzapine, in comparison with conventional medicines (haloperidol or diazepam) in a three-arm comparison for the sedation of acutely agitated patients in aeds. specifically, we aim to determine if administration of oral olanzapine (a)is more effective than sedation with oral haloperidol or oral diazepam alone; (b)is safer than sedation with comparison arms; (c)decreases the amount of subsequent redosing or alternative drugs required; (d)is more favourable than the haloperidol and diazepam arms with respect to safety, efficacy and adverse events. investigate potential variables leading to aed attendance and/or admission requiring oral sedation. these may include patient demographic and regular medications and adherence.

Eligibility criteria:
inclusion criteria: * accident \& emergency department patients * requiring oral drug sedation (as determined by an emergency clinician) will be enrolled. exclusion criteria: * known hypersensitivity or contraindication to the study drugs * reversible aetiology for agitation (e.g. hypotension, hypoxia, hypoglycaemia) * known pregnancy * acute alcohol withdrawal * refusal to take oral medication * patients from correctional facilities

Keywords: emergency emergency medicine sedation acute agitation
measuring musculoskeletal symptoms in patients receiving aromatase inhibitors

Conditions: Breast Cancer

Summary: current guidelines recommend endocrine treatment with aromatase inhibitors (ais) in post-menopausal women with hormone receptor-positive breast cancer. musculoskeletal symptoms are commonly reported with ai treatment,however, we do not have consistent methods to measure these symptoms prospectively. this gap in our knowledge inhibits the ability to test and develop treatments for ai-associated musculoskeletal symptoms. this pilot study will evaluate functional tests and standardized instruments for their ability to prospectively assess musculoskeletal symptoms in women being treated with ais for breast cancer.

specific aims: 1) identify a core set of instruments for measuring musculoskeletal symptoms, 2) model the time course and predictors of change in musculoskeletal symptoms, 3) explore the effect of musculoskeletal symptoms on adherence to ais in women during the first 6 months of ai treatment. methods: we will prospectively assess musculoskeletal symptoms due to treatment with aromatase inhibitors. post-menopausal women beginning ai treatment for hormone responsive breast cancer will be invited to join this study.

Eligibility criteria:
inclusion criteria: * women with stage i - iiia invasive breast cancer, * hormone-receptor positive cancer (either er+ or pr+ or both), * prescribed and have agreed to take exemestane, anastrazole or letrozole, * have completed initial treatment of surgery, rt, and/or chemotherapy, * are post-menopausal, * no previous history of aromatase inhibitor therapy for invasive breast cancer, * have signed the consent form. exclusion criteria: * history of rheumatoid arthritis, * unable to read or understand english, * history of psychiatric disability affecting informed consent or compliance with study procedures.

Keywords: breast cancer aromatase inhibitors musculoskeletal symptoms
transforaminal versus lateralized interlaminar cervical epidurals

Conditions: Cervicogenic Upper Extremity Radiculopathy

Summary: the purpose of this study is to compare two methods of giving epidural steroid injections for nerve pain in the arm that comes from the neck. an epidural steroid injection can be given in two different ways, either in the back of the spine within the neck or in the neck next to the nerve root going to the arm. both are standard medical treatments. the investigators would like to see how effective these treatments are, and if there are any differences in effectiveness or safety between these two routes.


Eligibility criteria:
inclusion criteria: * unilateral cervicogenic upper extremity radiculopathy (with or without accompanying neck pain) * baseline numerical pain scale (nrs) score \> 4 exclusion criteria: * recent (i.e., \< 2 months) cervical spine surgery * recent (i.e., \< 1 month) cervical epidural or upper extremity corticosteroid injection * contraindication or inability to the undergo procedure * inability to provide informed consent * expected inability to complete follow-up assessment * contraindication to receiving contrast material (precluding an epidurogram)

Keywords: ct-fluoroscopy corticosteroid injection
effects of cholinergic augmentation on measures of balance and gait

Conditions: Parkinson's Disease

Summary: this study will compare the effects of placebo and donepezil, a drug that helps conserve concentrations of the neurotransmitter, acetylcholine, on measures of balance and gait in subjects with parkinson's disease (pd). this study is a double-blind, placebo controlled, cross-over randomized clinical trial. short-latency afferent inhibition (sai), a physiological index of cholinergic function will be measured to determine if the deficits in balance and gait correlate with abnormalities of the sai and if sai is altered by donepezil as a measure of drug efficacy. cognitive tests like the attention network test (ant) will be administered to determine if changes in gait and balance are mediated by changes in attention. the results of this study will be the most direct test of the hypothesized role of cholinergic neurons and the neurotransmitter, acetylcholine in terms of gait and balance. the study is exploratory because it is not known whether donepezil will affect gait, balance or attention, nor which measures of gait, balance or attention will be sensitive to drug manipulation. the study's immediate goal is to determine the potential utility of cholinergic manipulation as a strategy for preventing or treating balance and gait dysfunction in pd. the findings of this trial are intended to lead to more sharply focused questions about the role of cholinergic neurons in balance and gait and eventually to phase ii b trials to determine clinical utility of cholinergic manipulation to prevent falls and improve mobility.


Eligibility criteria:
inclusion criteria: * 30 years old or older * diagnosis of idiopathic parkinson's disease * stand unassisted (without use of an assistance device) and walk continuously for at least 2 minutes. exclusion criteria: * musculoskeletal disorders that affect standing and walking * uncorrected vision disturbance * vestibular problems * major depression * hallucinations or other psychiatric disturbances * tachycardia * bradycardia * arrhythmias * peptic ulcer disease * use of anticholinergics * use of cholinesterase inhibitors * use of bladder antispasmodics * use of tricyclic antidepressants
the trajectory of fetal alcohol spectrum disorders (fasd) across the life span: continuing prevention and longitudinal epidemiology

Conditions: Fetal Alcohol Spectrum Disorders

Summary: screen women of childbearing age (15 - 44 years) for high risk drinking in antenatal clinics of the established research sites in the western cape province of south africa (sa). while there are multiple reasons for this screening, the purpose is for selective (secondary) prevention of fasd. a.) initiate a case control trial/efficacy study (n=400) of the use of one-session brief motivation enhancement therapy (met) in busy public health settings (versus information only) in these rich research sites where very high rates of fasd have been documented over the entirety of the past two decades. b.) these targeted prevention activities follow both findings and staff experience in prevention over the past decade which indicate that the most likely venue for prevention activities is in antenatal clinics of the local, primary care clinics and hospitals. these activities will also provide tangible community-level pay back for participation in ongoing research activities and lay the groundwork for sustainable services going forward.

the purpose of the research is to find out if motivational enhancement therapy is more effective than printed information alone (informational pamphlets only) in helping women reduce their risk of giving birth to children with fetal alcohol spectrum disorders (fasd) at primary health care facilities, in addition to evaluation individuals for risky health behaviors by having them complete brief screening questionnaires that give them information of how much risk they might be facing from their alcohol or other drug use. when a pregnant mother drinks alcohol, she puts her baby at risk. fasd is a group of growth, mental, and physical problems that may occur in a baby when a mother drinks alcohol during pregnancy.

Eligibility criteria:
inclusion criteria: * drinking pregnant women who are defined as women who: * drank in the 3 months prior to pregnancy and/or * drank alcohol at least once at any time during the prenatal period. * gestational age less than or equal to 16 weeks, but not more than 20 weeks at intake exclusion criteria: * non-drinking pregnant women who are defined as women who have not had any alcohol during the past 30 days. * gestational age \>20 weeks

Keywords: alcohol use and abuse prenatal alcohol use
immuno monitoring in patient with epithelial ovarian cancer eligible to parp inhibitors

Conditions: Ovarian Cancer

Summary: this study concerns the creation of a biological collection (blood samples) in patients with epithelial ovarian cancer in in order to describe the immune response with parp inhibitors.

the aim is to assess the impact of anti-parp on peripheral immune populations and the amount of dna circulating; to correlate these data with tumor infiltration, with the initial clinical characteristics and with the clinical course; compare the immunogenic effect of different anti-parps.

Eligibility criteria:
inclusion criteria: 1. patient over 18 years 2. patient treated for epithelial ovarian cancer 3. eligible for anti-parp therapy and in one of the 2 cohorts below: * cohort 1: maintenance treatment of adult patients with newly diagnosed advanced epithelial ovarian, fallopian tube or primary peritoneal cancer (figo stages iii and iv) with or without brca1/2 mutation, who have had a partial or complete response to first-line platinum-based chemotherapy. * 2nd cohort: single-agent maintenance treatment of adult patients with platinum-sensitive, recurrent primary epithelial ovarian, fallopian tube or peritoneal cancer who have responded (completely or partially) to platinum-based chemotherapy. 4. patient having signed the informed consent form. 5. patient fit and able to comply with the protocol for the duration of the study, including visits, scheduled sampling and follow-up. 6. patient affiliated to the social security system. exclusion criteria: 1. non-epithelial tumour of the ovary 2. patient unable to understand, read and/or sign informed consent. 3. current or previous use of immunosuppressive medication within 14 days prior to inclusion (except intranasal corticosteroids, systemic corticosteroids in physiological doses not exceeding 10 mg daily of prednisone or its equivalent, corticosteroids used as premedication for hypersensitivity reactions. 4. patient participating in other research that may modify the systemic treatment administered in the cohort in which she will be included. 5. pregnant or breast-feeding women. 6. hiv and/or hbv and/or hcv serology positive. 7. patient refusal. 8. person benefiting from a system of protection for adults (including guardianship, curatorship and safeguard of justice). 9. inability to undergo medical follow-up for geographical, social or psychological reasons.

Keywords: parp inhibitors immunomonitoring
feasibility study: accuracy of biomarker in detection of endometrial cancer

Conditions: Uterine Cancer; Endometrial Cancer

Summary: this study aims at developing an accurate, simple, and cost-effective method for screening and early detection of uterine cancers

the present study aims at developing an accurate, simple and cost-effective method for screening and early detection of uterine cancers in women using novel inventions and biotechnology methods for collection and assay of uterine cells. results of p2x7 assays using tissues obtained from women with known uterine cancer and from women with histologically normal endometrium will be compared. these data will also serve as basis for future studies to test the predictive value of the method in population-based studies.

Eligibility criteria:
inclusion criteria: * women scheduled to undergo hysterectomy * ages 18 years and older exclusion criteria: * pregnant women * students or employees under the direct supervision on the investigators.
trial of community health worker-led decision coaching

Conditions: Prostate Cancer

Summary: black men are disproportionately affected by prostate cancer, the most common non-cutaneous malignancy among men in the u.s. this randomized trial will evaluate the efficacy of a community health worker-led decision coaching program to facilitate shared decision making (sdm) and prostate specific antigen (psa) screening among black men with regards to decision quality, the decision making process, patient-provider communication and psa utilization for black men in the primary care setting.


Eligibility criteria:
inclusion criteria: patients: * black * male * attending fqhc for routine primary care appointment providers: * provider at sunset park health council federally qualified health center (fqhc) * caring for patients that fit inclusion criteria exclusion criteria: * provider at sunset park health council federally qualified health center (fqhc) * caring for patients that fit inclusion criteria
dose-dependent effect of fentanyl on cough attenuation during emergence from general anaesthesia

Conditions: Thyroid Neoplasm

Summary: fentanyl is expected to suppress tracheal tube-induced cough during emergence from general anaesthesia through binding to its receptors in the brainstem. however, it has not been proven if fentanyl has a complication-free, dose-dependent effect on cough suppression during emergence from sevoflurane anaesthesia. the purpose of this study is to evaluate the relationship between fentanyl doses and cough suppression during emergence from sevoflurane anaesthesia.


Eligibility criteria:
inclusion criteria: * the patients undergoing general anaesthesia for elective thyroidectomy due to thyroid neoplasm. * asa i-ii. * 20-59 years old. * female only. exclusion criteria: * signs of difficult intubation. * risks for perioperative pulmonary aspiration. * history of chronic respiratory disease. * recent upper respiratory track infection. * previous and recent smoking history